Advertisement

International Journal of Colorectal Disease

, Volume 26, Issue 7, pp 867–873 | Cite as

Optimal use of adjuvant chemotherapy in stage II colorectal cancer

  • Zhongguo Zhou
  • Xiaojun Wu
  • Ruojing Wang
  • Liren Li
  • Zhenhai Lu
  • Gong Chen
  • Yujing Fang
  • Zhizhong PanEmail author
Original Article

Abstract

Background and objective

The prognosis of stage II colorectal cancer varies. Whether or not to perform adjuvant chemotherapy on patients with stage II colorectal cancer is a controversial issue. The aims of this study were to identify relevant risk factors for the prognosis of stage II colorectal cancer and to evaluate the need for adjuvant chemotherapy.

Method

Between January 2000 and January 2005, 443 patients with stage II colorectal cancer who had received radical surgery at the Sun Yat-sen University Cancer Center were retrospectively analyzed. The overall survival rates and survival curves were analyzed using the Kaplan–Meier method and log–rank test. Univariate and multivariate prognostic analyses were performed using the Cox regression model. Patients with certain important risk factors were analyzed according to whether they received adjuvant chemotherapy, and four chemotherapeutic regimens were classified into sub-groups and analyzed.

Results

Univariate analyses showed that intestinal obstruction or perforation, type 2 diabetes mellitus, an inadequate surgical margin, and sampling of less than 12 lymph nodes were risk factors that correlated with poor prognosis. Patients with an intestinal obstruction or perforation and insufficient lymph node samples achieved higher 5-year survival rates with adjuvant chemotherapy than with surgery alone.

Conclusion

Intestinal obstruction or perforation, sampling of less than 12 lymph nodes, and inadequate surgical margins were identified as risk factors for poor survival, and patients with either of the first two factors benefited from adjuvant chemotherapy. Moreover, the use of capecitabine alone may be insufficient for patients with an intestinal obstruction or perforation.

Keywords

Stage II colorectal cancer Risk factors Chemotherapy 

Notes

Acknowledgment

This work was supported by grants from the GuangDong Scientific Planning Project, China (no. 2008B030301119), and GuangDong Medical Research Funds, China (no. B2007071, B2008057).

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71–96PubMedCrossRefGoogle Scholar
  2. 2.
    Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL, Bear HD, Atkins JN, Dimitrov NV, Glass AG, Fisher ER, Fisher B (1999) Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17(11):3553–3559PubMedGoogle Scholar
  3. 3.
    Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122(5):321–326PubMedGoogle Scholar
  4. 4.
    Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370(9604):2020–2029PubMedCrossRefGoogle Scholar
  5. 5.
    Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22(16):3408–3419PubMedCrossRefGoogle Scholar
  6. 6.
    Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L (2004) Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 22(16):3395–3407PubMedCrossRefGoogle Scholar
  7. 7.
    Andre T, Sargent D, Tabernero J, O'Connell M, Buyse M, Sobrero A, Misset JL, Boni C, de Gramont A (2006) Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol 13(6):887–898PubMedCrossRefGoogle Scholar
  8. 8.
    Johnston PG (2005) Stage II colorectal cancer: to treat or not to treat. Oncologist 10(5):332–334PubMedCrossRefGoogle Scholar
  9. 9.
    Ho YH, Siu SK, Buttner P, Stevenson A, Lumley J, Stitz R (2010) The effect of obstruction and perforation on colorectal cancer disease-free survival. World J Surg 34(5):1091–1101PubMedCrossRefGoogle Scholar
  10. 10.
    Helyer LK, Law CH, Butler M, Last LD, Smith AJ, Wright FC (2007) Surgery as a bridge to palliative chemotherapy in patients with malignant bowel obstruction from colorectal cancer. Ann Surg Oncol 14(4):1264–1271PubMedCrossRefGoogle Scholar
  11. 11.
    Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45(4):291–297PubMedCrossRefGoogle Scholar
  12. 12.
    Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34(8):1274–1281PubMedCrossRefGoogle Scholar
  13. 13.
    Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19(21):4097–4106PubMedGoogle Scholar
  14. 14.
    Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19(8):2282–2292PubMedGoogle Scholar
  15. 15.
    Chan AK, Wong AO, Jenken DA (2010) Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer–is it equivalent to 5-FU infusion plus leucovorin and radiotherapy? Int J Radiat Oncol Biol Phys 76(5):1413–1419PubMedCrossRefGoogle Scholar
  16. 16.
    Limburg PJ, Vierkant RA, Fredericksen ZS, Leibson CL, Rizza RA, Gupta AK, Ahlquist DA, Melton LJ 3rd, Sellers TA, Cerhan JR (2006) Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol 101(8):1872–1879PubMedCrossRefGoogle Scholar
  17. 17.
    Reinmuth N, Fan F, Liu W, Parikh AA, Stoeltzing O, Jung YD, Bucana CD, Radinsky R, Gallick GE, Ellis LM (2002) Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 82(10):1377–1389PubMedGoogle Scholar
  18. 18.
    Leo E, Belli F, Miceli R, Mariani L, Gallino G, Battaglia L, Vannelli A, Andreola S (2009) Distal clearance margin of 1 cm or less: a safe distance in lower rectum cancer surgery. Int J Colorectal Dis 24(3):317–322PubMedCrossRefGoogle Scholar
  19. 19.
    Pan ZZ, Wan DS, Zhang CQ, Shao JY, Li LR, Chen G, Zhou ZW, Wang FL (2006) Using p53-immunostained large specimens to determine the distal intramural spread margin of rectal cancer. World J Gastroenterol 12(10):1626–1629PubMedGoogle Scholar
  20. 20.
    Bozzetti F, Mariani L, Miceli R, Montalto F, Baratti D, Andreola S (1997) Impact of distal clearance margin on oncologic outcome after restorative resection of the rectum. Tumori 83(6):907–911PubMedGoogle Scholar
  21. 21.
    Tepper JE, O'Connell MJ, Niedzwiecki D, Hollis D, Compton C, Benson AB 3rd, Cummings B, Gunderson L, Macdonald JS, Mayer RJ (2001) Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 19(1):157–163PubMedGoogle Scholar
  22. 22.
    Cianchi F, Palomba A, Boddi V, Messerini L, Pucciani F, Perigli G, Bechi P, Cortesini C (2002) Lymph node recovery from colorectal tumor specimens: recommendation for a minimum number of lymph nodes to be examined. World J Surg 26(3):384–389PubMedCrossRefGoogle Scholar
  23. 23.
    Swanson RS, Compton CC, Stewart AK, Bland KI (2003) The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 10(1):65–71PubMedCrossRefGoogle Scholar
  24. 24.
    Tsai HL, Lu CY, Hsieh JS, Wu DC, Jan CM, Chai CY, Chu KS, Chan HM, Wang JY (2007) The prognostic significance of total lymph node harvest in patients with T2-4N0M0 colorectal cancer. J Gastrointest Surg 11(5):660–665PubMedCrossRefGoogle Scholar
  25. 25.
    Vather R, Sammour T, Zargar-Shoshtari K, Metcalf P, Connolly A, Hill A (2009) Lymph node examination as a predictor of long-term outcome in Dukes B colon cancer. Int J Colorectal Dis 24(3):283–288PubMedCrossRefGoogle Scholar
  26. 26.
    Karlberg M, Ohrling K, Edler D, Hallstrom M, Ullen H, Ragnhammar P (2010) Prognostic and predictive value of thymidylate synthase expression in primary colorectal cancer. Anticancer Res 30(2):645–651PubMedGoogle Scholar
  27. 27.
    Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ (2009) Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol 32(1):38–43PubMedCrossRefGoogle Scholar
  28. 28.
    Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson AB 3rd, Hamilton SR (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344(16):1196–1206PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Zhongguo Zhou
    • 1
    • 2
    • 3
  • Xiaojun Wu
    • 1
    • 3
  • Ruojing Wang
    • 4
  • Liren Li
    • 1
    • 3
  • Zhenhai Lu
    • 1
    • 3
  • Gong Chen
    • 1
    • 3
  • Yujing Fang
    • 1
    • 3
  • Zhizhong Pan
    • 3
    • 1
    Email author
  1. 1.Department of Colorectal SurgerySun Yat-sen University Cancer CenterGuangzhouPeople’s Republic of China
  2. 2.Department of Molecular and Cellular OncologyUniversity of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.State Key Laboratory of Oncology in South ChinaGuangzhouPeople’s Republic of China
  4. 4.Department of General SurgeryThe First Affiliated Hospital of Sun Yat-sen UniversityGuangzhouPeople’s Republic of China

Personalised recommendations